Literature DB >> 15481454

Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with chronic active Epstein-Barr virus infection.

Kenji Tamayose, Motoki Egashira, Koichi Sugimoto, Jun Ando, Shigeo Mori, Kazuo Oshimi.   

Abstract

Entities:  

Mesh:

Year:  2004        PMID: 15481454     DOI: 10.1532/ijh97.04076

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

1.  Clinical and virologic characteristics of chronic active Epstein-Barr virus infection.

Authors:  H Kimura; Y Hoshino; H Kanegane; I Tsuge; T Okamura; K Kawa; T Morishima
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

2.  Chronic, symptomatic Epstein-Barr virus infections.

Authors:  A B Rickinson
Journal:  Immunol Today       Date:  1986-01

Review 3.  Chronic, active Epstein-Barr virus infection.

Authors:  D M Maia; A L Peace-Brewer
Journal:  Curr Opin Hematol       Date:  2000-01       Impact factor: 3.284

4.  Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection.

Authors:  M Tobi; A Morag; Z Ravid; I Chowers; V Feldman-Weiss; Y Michaeli; E Ben-Chetrit; M Shalit; H Knobler
Journal:  Lancet       Date:  1982-01-09       Impact factor: 79.321

Review 5.  The molecular basis for the generation of Hodgkin and Reed-Sternberg cells in Hodgkin's lymphoma.

Authors:  Im-Soon Lee; Seok Hyung Kim; Hyung Geun Song; Seong Hoe Park
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

Review 6.  Diagnosis and treatment of Epstein-Barr virus-associated natural killer cell lymphoproliferative disease.

Authors:  Keisei Kawa
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

7.  Clinicopathological study of severe chronic active Epstein-Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome.

Authors:  K Ohshima; J Suzumiya; M Sugihara; S Nagafuchi; S Ohga; M Kikuchi
Journal:  Pathol Int       Date:  1998-12       Impact factor: 2.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.